Apogeissoschizin






Names

    • Apogeissoschizin

Attributes

  • Canonical SMILES

    C/C=C1CN(CC2)[C@@]3([H])CC/1/C(C(OC)=O)=C\CN4C(C=CC=C5)=C5C2=C34

  • InChI

    InChI=1S/C22H24N2O2/c1-3-14-13-23-10-8-16-15-6-4-5-7-19(15)24-11-9-17(22(25)26-2)18(14)12-20(23)21(16)24/h3-7,9,18,20H,8,10-13H2,1-2H3/b14-3-,17-9+/t18?,20-/m0/s1

  • Molecule Class: Alkaloids
  • TPSA: 34.47
  • #RotBonds: 1
  • MW: 348.4460000000001
  • HBD: 0
  • HBA: 4
  • logP: 3.6197000000000026
  • Chemical Formula: C22H24N2O2


Species

    Species Place of Collection NCBI Taxonomy Voucher Specimen
    T. bufalina China 403123 Cai20170220

External Databases


References

  • Alkaloids isolated from Tabernaemontana bufalina display xanthine oxidase inhibitory activity. Phytochemistry, 2019 (PMID 31302343).

Compound-Protein Relationships

  • No relationship found

Compound Activities

    • Xanthine oxidase inhibitory

Predicted NMR Spectral Data


Predicted MS Fragmentation Pattern

    N.B.: It is recommended to zoom in on a specific area of an MS plot before hovering on a peak.

Predicted ADMET Properties

    Property Model Name Predicted Value
    Absorption Caco-2 (logPaap) -4.82
    Human Oral Bioavailability 20% Bioavailable
    Human Intestinal Absorption Absorbed
    Madin-Darby Canine Kidney -4.67
    Human Oral Bioavailability 50% Non-Bioavailable
    P-Glycoprotein Inhibitor Non-Inhibitor
    P-Glycoprotein Substrate Substrate
    Skin Permeability -2.43
    Distribution Blood-Brain Barrier (Central Nervous System) -2.27
    Blood-Brain Barrier Penetrable
    Fraction Unbound (Human) 1.29
    Plasma Protein Binding 65.51
    Steady State Volume of Distribution 5.9
    Metabolism Breast Cancer Resistance Protein Non-Inhibitor
    CYP 1A2 Inhibitor Inhibitor
    CYP 1A2 substrate Substrate
    CYP 2C19 Inhibitor Non-Inhibitor
    CYP 2C19 substrate Substrate
    CYP 2C9 Inhibitor Non-Inhibitor
    CYP 2C9 Substrate Substrate
    CYP 2D6 Inhibitor Non-Inhibitor
    CYP 2D6 Substrate Substrate
    CYP 3A4 Inhibitor Non-Inhibitor
    CYP 3A4 Substrate Substrate
    OATP1B1 Non-Inhibitor
    OATP1B3 Non-Inhibitor
    Excretion Clearance 7.41
    Organic Cation Transporter 2 Inhibitor
    Half-Life of Drug Half-Life < 3hs
    Toxicity AMES Mutagenesis Safe
    Avian Safe
    Bee Toxic
    Bioconcentration Factor 0.81
    Biodegradation Safe
    Carcinogenesis Safe
    Crustacean Toxic
    Liver Injury I Safe
    Eye Corrosion Safe
    Eye irritation Safe
    Maximum Tolerated Dose -0.24
    Liver Injury II Toxic
    hERG Blockers Toxic
    Daphnia Maga 6.28
    Micronucleos Toxic
    NR-AhR Safe
    NR-AR Safe
    NR-AR-LBD Safe
    NR-Aromatase Safe
    NR-ER Safe
    NR-ER-LBD Safe
    NR-GR Safe
    NR-PPAR-gamma Safe
    NR-TR Safe
    T. Pyriformis -6.51
    Rat (Acute) 2.86
    Rat (Chronic Oral) 1.85
    Fathead Minnow 5.0
    Respiratory Disease Toxic
    Skin Sensitisation Toxic
    SR-ATAD5 Safe
    SR-ARE Safe
    SR-HSE Safe
    SR-MMP Safe
    SR-p53 Safe
    General Properties Boiling Point 447.82
    Hydration Free Energy -4.87
    Log(D) at pH=7.4 3.72
    Log(P) 3.9
    Log S -3.04
    Log(Vapor Pressure) -7.85
    Melting Point 170.31
    pKa Acid 9.91
    pKa Basic 7.44